Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 15/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | MLNR | O43193 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3032974 | 0.91 | PDE4B (0.51) | PDE4BCYP3A4PDE4DKCNH2MLNR | |
| SCHEMBL3032976 | 0.91 | PDE4B (0.51) | PDE4BCYP3A4PDE4DKCNH2MLNR | |
| SCHEMBL10271617 | 0.89 | PDE4B (0.41) | PDE4BJAK1PARP1PARP2PDE4D | |
| SCHEMBL10271668 | 0.88 | PARP1 (0.39) | PDE4BJAK1PARP1PARP2PDE4D | |
| SCHEMBL8168986 | 0.88 | PARP1 (0.39) | PDE4BJAK1PARP1PARP2PDE4D | |
| SCHEMBL8185505 | 0.88 | PDE4B (0.46) | PDE4BJAK1PARP1PARP2PDE4D | |
| SCHEMBL10272053 | 0.88 | PARP1 (0.38) | PDE4BJAK1PARP1PARP2 | |
| SCHEMBL8193271 | 0.88 | PARP1 (0.38) | PDE4BJAK1PARP1PARP2 | |
| SCHEMBL10271670 | 0.88 | PDE4B (0.46) | PDE4BJAK1PARP1PARP2PDE4D | |
| SCHEMBL10221633 | 0.87 | CKS1B (0.42) | PDE4BJAK1PDE4DKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2106396-B1 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ALCON RES LTD (US) | 2014-09-24 | — | — | EP | disclosed |
| US-20120077801-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2012-03-29 | — | — | US | disclosed |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | ALCON RESEARCH, LTD. | 2010-08-12 | — | — | US | disclosed |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | ALCON RESEARCH, LTD. | 2010-08-12 | — | — | US | disclosed |
| US-20090124596-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2009-05-14 | — | — | US | disclosed |
| US-20090124596-A1 | Chemical Compounds 637 | ALCON RESEARCH, LTD. | 2009-05-14 | — | — | US | disclosed |
| WO-2008084223-A2 | CHEMICAL COMPOUNDS 637: PYRIDOPYRIMIDINEDIONES AS PDE4 INHIBITORS | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077801-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | PDE4B 2/4885CYP3A4 116/4885JAK1 1685/4885 |
| US-20090124596-A1 | Chemical Compounds 637 | PDE4A, PDE4B, PDE3B | PDE4B 2/4885CYP3A4 116/4885JAK1 1685/4885 |
| US-20100204203-A1 | Chemical Compounds 637: Pyridopyrimidinediones as PDE4 Inhibitors | PDE4A, PDE4B, PDE5A | PDE4B 2/4885CYP3A4 73/4885JAK1 1906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.